Labelling of blood platelets with stable tracers

Area of Science:

• Hematology
• Nuclear Medicine
• Biomedical Engineering

Background:

• Platelet kinetics are crucial for understanding various hematological disorders.
• Chromium-51 (Cr51) is a common radioisotope for labeling platelets but has limitations.
• Development of alternative, stable labeling methods for platelets is of significant interest.

Purpose of the Study:

• To compare the half-time of platelets labeled with stable rubidium (Rb) to those labeled with chromium-51 (Cr51).
• To evaluate the feasibility of using stable rubidium for platelet labeling and kinetic studies.

Main Methods:

• Platelets were labeled with stable rubidium and chromium-51.
• Quantification of rubidium incorporation using X-ray fluorescence.
• In vitro and in vivo half-time measurements of labeled platelets in humans and rabbits.
• Statistical comparison of half-life data between Rb- and Cr51-labeled platelets.

Main Results:

• The mean quantity of rubidium incorporated was approximately several micrograms per ml of blood.
• In vitro half-time for human Rb-labeled platelets was 41.2 ± 3h, compared to 44.8 ± 3h for Cr51-labeled platelets.
• In vivo half-time for rabbit Rb-labeled platelets was 22 ± 3h, compared to 18 ± 3h for Cr51-labeled platelets.

Conclusions:

• Stable rubidium labeling of platelets demonstrates comparable in vitro and in vivo kinetics to Cr51 labeling.
• Rubidium labeling, assayed by X-ray fluorescence, presents a potentially simpler and effective alternative for platelet kinetic studies.
• Further research may explore the clinical applicability of rubidium-labeled platelets.